Pembrolizumab for Early Triple-Negative Breast CancerPeter Schmid, Joyce O’Shaughnessy, Javier Cortés et al.|New England Journal of Medicine|2020Cited by 3.1k
Measurement of Residual Breast Cancer Burden to Predict Survival After Neoadjuvant ChemotherapyW. Fraser Symmans, Lajos Pusztai|Journal of Clinical Oncology|2007Cited by 1.6k
Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-upSibylle Loibl, Nadia Harbeck, Fabrice André et al.|Annals of Oncology|2023Cited by 830
A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT)Joaquı́n Mateo, Lajos Pusztai|Annals of Oncology|2018Cited by 774
Effect of Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women With Early-Stage Breast CancerRita Nanda, Laura J. Esserman, Minetta C. Liu et al.|JAMA Oncology|2020Cited by 707